Keyword: Regeneron Pharmaceuticals
The FDA has issued a CRL for Regeneron's application to extend the dosing schedule for blockbuster Eylea from eight to 12 weeks.
Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.
Amgen's aggressive legal bid to push Sanofi and Regeneron's rival PCSK9 drug off the market didn't work, but the big biotech hasn't given up.
Eylea may be falling short, but never fear, executives said Thursday: We're all over it.
As much as Sanofi has struggled with diabetes the past few years, it could typically count on vaccines and Genzyme—but not this quarter.
Roche sued Lilly Tuesday, claiming the two-year-old psoriasis med Taltz steps on one of its patents. Thing is, Roche just won that patent this week.
Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.
Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.
Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.
Regeneron's George Yancopoulos won a bonus of sorts in 2012, and now he's vested. This year, though, he and CEO Len Schliefer took a small cut.